The National Center for Advancing Translational Sciences (NCATS) has funding opportunities open for small business biotech entrepreneurs and researchers under the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
2019 Omnibus Grant Solicitation: due Sept. 5, 2019 and Jan. 5, 2020
Small businesses and research organizations involved in commercializing innovative medical technologies are encouraged to apply for the 2019 Omnibus Grant Solicitations (SBIR: PA-19-272) and STTR: PA-19-270 ). If you have your application almost ready, be sure to submit before the Sept. 5, 2019 deadline. The next deadline will be January 5, 2020. NCATS is particularly interested in applications that address research areas relevant to any stage of translation, from target validation through pre-clinical and clinical evaluation, to intervention implementation and dissemination, including:
SBIR and STTR applicants can apply for Phase I and Phase II funding
. SBIR applicants can also now opt to apply for Direct-to-Phase II Funding
. This award allows small businesses to submit Direct-to-Phase II SBIR applications if the small business has performed the Phase I stage-type research through other funding sources
. An updated SBIR/STTR Application Guide
with additional instructions for the newly reinstated SBIR Direct Phase II application preparation and submission is now available.
2020 Contract Topics Solicitation: due Oct. 23, 2019
NCATS is soliciting applications for the 2020 SBIR contract solicitation (PHS 2020-1), due Oct. 23, 2019. The topic is “Alternatives to commercially available cell culture insert membranes and manufacturing techniques (Contract Topic #019).”
Applicants are strongly encouraged to carefully read the contract solicitation for eligibility, detailed information about the topic and awards, as well as submission information and timelines. To submit your proposal, you must use the eCPS. No other method of proposal submission is permitted.
For questions on NCATS SBIR contract topics, please contact NCATS Contracting Officer Jeffrey Schmidt at email@example.com.
- Funding is stable, predictable and not a loan
- Capital is non-dilutive
- Small businesses and research organizations retain intellectual property rights
- NIH’s rigorous peer-review provides recognition, validation and visibility to early-stage companies
- Prestige associated with these awards can help attract more funding or other support (e.g., venture capital, strategic partners)